Navigation path

Page navigation

Note: Fields marked with * are mandatory

Myeloid U937 Skin Sensitisation Test

Topic : Skin sensitisation

Test Method Number: TM2009-05 (EU)
Short Name of TM: MUSST
Year received: 2009
Responsible Organisation: EURL ECVAM - European Union '
General Comments:

Validation stopped. New submission with new protocol received under TM2013-02 (U-Sens)

Succeeding TM: TM2013-02 - U-SENS™ - Myeloid U937 Skin Sensitisation Test

Method Description

The MUSST assay supports the discrimination between sensitizing and non-sensitizing chemicals. It addresses one of the biological mechanisms described under key event 3 (events in dendritic cells (DC)) of the skin sensitization Adverse Outcome Pathway (AOP) by measuring the induction of the CD86 protein marker in U937 cells.

The U937 cells are human myeloid cells used as surrogate model for DCs. U937 is a cell line established from a diffuse histiocytic lymphoma with the advantage of higher stability and the easiness of maintenance compared to human-blood derived DCs. The CD86 protein marker is a costimulatory factor which is upregulated in mature DCs and plays a pivotal role in antigen presentation and subsequent T cell priming. In the MUSST test method, the modulation of the FITC-labeled anti-CD86 in U937 cells is measured by flow cytometry after a 48 hours exposure to test chemicals.

Track Approval Status

  • Submission
  • Validation
  • Peer-review
  • Recommendation
  • Regulatory acceptance/Standards
StepExpand All
 SubmissionShow status
 ValidationShow status
 Regulatory acceptance/Standards